atorvastatin has been researched along with Atrophy in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Cao, T; Ding, W; Fan, GC; Li, H; Liang, L; Peng, T; Qu, L | 1 |
Alfano, B; Amato, MP; Annunziata, P; Bellantonio, P; Bonavita, V; Brescia Morra, V; Brunetti, A; Comerci, M; Florio, C; Francia, A; Grimaldi, LM; Lanzillo, R; Marini, S; Marrosu, MG; Orefice, G; Pozzilli, C; Quarantelli, M; Tedeschi, G; Trojano, M | 1 |
Ao, Q; Cheng, Q; Hu, Y; Liu, S; Liu, Y; Yang, G; Ye, P; Zhao, J | 1 |
Campistol Plana, JM | 1 |
Bouwels, L; de Leeuw, FE; Enajat, M; Pop, G; Pop-Purceleanu, M; Tendolkar, I; van Kuilenburg, J; van Wingen, G; Zwiers, MP | 1 |
Bottinelli, R; D'Antona, G; Mascaro, A; Miglietta, D; Monopoli, A; Ongini, E | 1 |
Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, JY; Kim, M; Lee, ST; Roh, JK | 1 |
1 review(s) available for atorvastatin and Atrophy
Article | Year |
---|---|
[Chronic transplant nephropathy].
Topics: Animals; Atorvastatin; Atrophy; Biopsy; Chronic Disease; Complement C4b; Heptanoic Acids; Humans; Kidney Transplantation; Kidney Tubules; Nephritis, Interstitial; Peptide Fragments; Postoperative Complications; Pyridoxamine; Pyrroles; Rats; Risk Factors; Terminology as Topic; Transplants | 2008 |
2 trial(s) available for atorvastatin and Atrophy
Article | Year |
---|---|
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Topics: Adult; Atorvastatin; Atrophy; Brain; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Italy; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Patient Dropouts; Time Factors; Treatment Outcome | 2016 |
One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Atrophy; Azetidines; Biomarkers; Cholesterol; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Memory; Memory Disorders; Neuropsychological Tests; Pyrroles; Temporal Lobe | 2012 |
4 other study(ies) available for atorvastatin and Atrophy
Article | Year |
---|---|
Pharmacological inhibition of Rac1 attenuates myocardial abnormalities in tail-suspended mice.
Topics: Animals; Atorvastatin; Atrophy; Mice; Myocytes, Cardiac; NADPH Oxidases; rac1 GTP-Binding Protein; Reactive Oxygen Species; Tail | 2022 |
Atorvastatin improves pathological changes in the aged kidney by upregulating peroxisome proliferator-activated receptor expression and reducing matrix metalloproteinase-9 and transforming growth factor-β1 levels.
Topics: Age Factors; Animals; Atorvastatin; Atrophy; Down-Regulation; Female; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Matrix Metalloproteinase 9; Peroxisome Proliferator-Activated Receptors; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta1; Up-Regulation | 2016 |
Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice.
Topics: Animals; Atorvastatin; Atrophy; Citrate (si)-Synthase; Creatine Kinase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myosin Heavy Chains; Nitric Oxide; Nitric Oxide Donors; Pyrroles | 2013 |
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Atrophy; Brain; Cell Death; Cerebral Hemorrhage; Hematoma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Models, Animal; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |